Image de couverture de livre

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nipun Verma, Pratibha Garg, Arun Valsan, Akash Roy, Saurabh Mishra, Parminder Kaur, Sahaj Rathi, Arka De, Madhumita Premkumar, Sunil Taneja, Virendra Singh, Radha K. Dhiman, Ajay K. Duseja, Patrick Kamath
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
par: Parminder Kaur, et autres
Publié: (2024)

Epidemiology, Predictors of Antimicrobial Resistance and Empiric Treatment Strategies for Spontaneous Bacterial Peritonitis in Cirrhosis: A Multicentre SBP ‐ INDIA Study
par: Nipun Verma, et autres
Publié: (2026)

Review article: Evaluation and care of the critically ill patient with cirrhosis
par: Iva Kosuta, et autres
Publié: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
par: Nipun Verma, et autres
Publié: (2024)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply
par: Rohit Mehtani, et autres
Publié: (2026)

Racial and ethnic disparities in post‐liver transplant outcomes for patients with acute‐on‐chronic liver failure: An analysis of the UNOS database
par: David Uihwan Lee, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
par: Basile Njei, et autres
Publié: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
par: Mohamed I. Elsaid, et autres
Publié: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
par: Stuart McPherson, et autres
Publié: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
par: Sung Won Chung, et autres
Publié: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
par: Jian Wang, et autres
Publié: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
par: C. Stephens
Publié: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
par: Nobuharu Tamaki, et autres
Publié: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
par: Nobuharu Tamaki, et autres
Publié: (2024)

An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor‐induced liver injury
par: Mar Riveiro‐Barciela, et autres
Publié: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
par: Xianhua Mao, et autres
Publié: (2024)

Editorial: The future of managing drug induced liver injury
par: Amanda Nicoll
Publié: (2024)

Review article: Oesophageal disorders in chronic liver disease
par: Francisco Idalsoaga, et autres
Publié: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
par: Yewan Park, et autres
Publié: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
par: Shusuke Kumazaki, et autres
Publié: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
par: Yaomin Wang, et autres
Publié: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
par: Carolin V. Schneider, et autres
Publié: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
par: Deepak Joshi, et autres
Publié: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
par: Zhuo Li, et autres
Publié: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
par: Pojsakorn Danpanichkul, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
par: Richie Manikat, et autres
Publié: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
par: Ivan Arcari, et autres
Publié: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
par: Nina Dominik, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
par: Abdel‐Aziz Shaheen, et autres
Publié: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
par: Anthony Croft, et autres
Publié: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
par: Donghee Kim, et autres
Publié: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
par: Jannis Kountouras, et autres
Publié: (2024)

Characterisation of an outbreak of acute liver injury after ingestion of plant‐based food supplement
par: Gina Choi, et autres
Publié: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
par: Manya Prasad, et autres
Publié: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
par: Nabil Noureddin, et autres
Publié: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
par: Carolin V. Schneider, et autres
Publié: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
par: Eunice X. X. Tan, et autres
Publié: (2024)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
par: Victoria T. Kronsten, et autres
Publié: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
par: María Hernández‐Pérez, et autres
Publié: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
par: Samer Gawrieh, et autres
Publié: (2024)